High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. Although some patients exhibit deep and durable responses to venetoclax as a single agent, other patients harbor subpopulations of resi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Oppermann, Sina, Ylanko, Jarkko, Shi, Yonghong, Hariharan, Santosh, Oakes, Christopher C., Brauer, Patrick M., Zúñiga-Pflücker, Juan C., Leber, Brian, Spaner, David E., Andrews, David W.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2016
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5000578/
https://ncbi.nlm.nih.gov/pubmed/27297795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-12-687814
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars